- H.C. Wainwright set a new price target of $455.00 for Alnylam Pharmaceuticals (NASDAQ:ALNY), indicating an 88.97% potential upside for the biopharmaceutical stock.
- The company's stock dropped 28.30% following a Q2 2026 earnings miss, with adjusted earnings of $1.84 per share and revenues of $1.29 billion falling short of analyst expectations.
- Despite lowered sales guidance for its TTR products, Alnylam reported robust 67% year-over-year total revenue growth and strong sales for its lead drug, Amvuttra, exceeding $1 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) is a biopharmaceutical company that focuses on developing RNA interference (RNAi) therapeutics. These are advanced drugs designed to treat rare genetic diseases by targeting their root cause. The company operates in a highly competitive and innovative sector of the healthcare industry, driving significant advancements in genetic medicine.
On August 4, 2026, analyst firm H.C. Wainwright adjusted its price target for Alnylam to $455.00. A price target is an analyst's estimate of a stock's future value. When the target was announced, the stock's price was $215.61. This new target represents a potential increase of 88.97% from that price, signaling strong analyst confidence in Alnylam's future performance and drug pipeline.
This analyst rating follows a period of volatility for the company. As highlighted by Zacks, Alnylam's stock dropped 28.30% after its second-quarter 2026 earnings report. The company's adjusted earnings of $1.84 per share missed the estimated $2.05, and revenues of $1.29 billion also fell short of the $1.32 billion expectation, impacting investor sentiment.
The negative market reaction was largely due to the company lowering its sales guidance for its TTR products for the full year 2026. This guidance cut led to investor losses and has resulted in ongoing investigations by law firms, including Glancy Prongay Wolke & Rotter LLP, for potential securities law violations related to the financial disclosures.
Despite the lowered guidance, the company's total revenues grew 67% year-over-year, demonstrating strong underlying business momentum. Sales for its lead drug, Amvuttra, exceeded $1 billion in the quarter, highlighting its market success. Alnylam also raised its outlook for collaboration and royalty revenue, citing higher royalties from its partners, which could provide additional financial stability and growth.